Role of HGF/MET axis in resistance of lung cancer to contemporary management

Lung cancer: present-day portrait

Epidemiology

As per 2008 estimates, lung cancer accounts for 1.6 million new cancer cases (13% of all new cancers) and about 1.4 million cancer deaths (18% of all cancer deaths) worldwide, making it the number one cause of cancer related mortality (1). In the United States alone, about 226,160 new lung cancer cases and about 160,340 lung cancer deaths are estimated to occur in 2012 (2). About 85% of all lung cancers are histologically non-small cell lung cancers (NSCLC) and 15% are small-cell lung cancers (SCLC) (3). As per incidence statistics of 1990-2000 and 2000-2009, 40-80% of all NSCLC are localized and the remaining present as either advanced loco-regional disease or with distant metastasis [National Cancer Institute: Surveillance Epidemiology and End Results (NCI: SEER) (seer.cancer.gov)] (4,5). Similarly, 40% of patients with SCLC are staged with limited-stage disease and 60% are staged with extensive-stage disease (6).

Contemporary therapies

The treatment of lung cancer is multifaceted and involves a complex interplay of surgery, radiation, cytotoxic chemotherapy and targeted therapies (5). Accurate staging and stage dependent multidisciplinary care is paramount to improved patient outcomes. The distinction between NSCLC and SCLC guides treatment and prognosis. In NSCLC, although complete surgical resection can result in long-term survival, a significant majority of patients, 50% with stage IB and 70% of stage II, recur (5). Addition of adjuvant platinum-based chemotherapy demonstrated improved survival in early stage NSCLC (7). Radiation therapy is employed for treatment of NSCLC in both the palliative setting and for definitive management of unresectable non-metastatic disease either alone or with concurrent chemotherapy (8-10). Palliative systemic therapy in patients with stage IV NSCLC with either disseminated metastases or malignant effusions is enhanced by molecular characterization including mutational profiles. Cytotoxic chemotherapy forms the backbone of therapy for NSCLC (11). Active agents against NSCLC are platinum compounds (cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), vinorelbine, gemcitabine and pemetrexed (11-13). Multiple targeted agents have also demonstrated activity in metastatic NSCLC. Tumors that exhibit anaplastic lymphoma kinase (ALK) fusions and epidermal growth factor receptor (EGFR) mutations are treated with ALK inhibitor (Crizotinib) and EGFR inhibitor (erlotinib), respectively (14,15). Targeted agents such as bevacizumab against vascular endothelial growth factor (VEGF) and cetuximab against EGFR in combination with chemotherapy doublets have shown a significant survival benefit in NSCLC (16,17). The management of limited-stage SCLC (LS-SCLC) involves combination chemotherapy with a platinum-based regimen (cisplatin/carboplatin and etoposide/irinotecan/epirubicin/topotecan) in conjunction with concurrent accelerated thoracic radiation therapy, while extensive-stage SCLC (ES-SCLC) is treated with, combination platinum-based chemotherapy (carboplatin and etoposide) alone (18-22). This treatment plan and combined modality approach can be tailored to individuals depending on patient specific factors such as age, performance status, pulmonary functions and comorbidities.

Prognosis

Despite multiple available treatments the overall prognosis of lung cancer remains dismal. The clinical/pathological stage of disease presentation is the single most important prognostic determinant in lung cancer (4). In a large series of patients with NSCLC, median overall survival varied from about 60 months for clinical stage I disease to about 6 months for clinical stage IV disease (4). The 5-year overall survival rate for LS-SCLC and ES-SCLC is 4.8% and 2.3%, respectively. Median disease-free survival in stage I and II NSCLC after resection and adjuvant therapy is about 3 years (23). Response rates and median survival of patients with stage III NSCLC treated with concurrent chemoradiation are 84% and 16.5 months, respectively (24). Patients receiving chemotherapy and/or targeted therapy in metastatic setting have objective response rates of about 35% and median survival of about 12.3 months (16). Similarly, response rates and median overall survival in ES-SCLC is 60% and 11 months, respectively (19).

These figures indicate that current therapies have limited efficacy and even when initial responses are seen, these are short lasting. Tackling primary and acquired resistance to existing therapies is a major challenge in improving patient outcomes in lung cancer.

The MET/HGF pathway: an overview

Structure & function

The proto-oncogene cMET (mesenchymal-epithelial transition factor gene) is present on chromosome 7q31 and encodes for a receptor tyrosine kinase (RTK) (25). The MET receptor is a single-pass type I transmembrane disulfide-linked heterodimer protein, made of a short extracellular alpha-chain and a long transmembrane beta-chain (26,27). The beta-chain has an extracellular, a transmembrane and a cytoplasmic domain (26). The cytoplasmic portion of the beta-chain contains the kinase domain of the RTK and also the carboxy-terminal tail with the bidentate multifunctional docking site, essential for intracellular signaling (26,28). HGF or scatter factor (SF) has been identified as the ligand for the MET receptor (29). HGF is a heterodimer, composed of a large alpha-chain and a small beta-chain linked by disulfide bridges (26,30). The ligand HGF dimer binds to the N-terminal portion of MET and causes dimerization of MET receptors (31,32).

The receptor-ligand interaction between MET and HGF, and the resultant dimerization ultimately lead to the activation of the intrinsic kinase activity of MET, which in-turn phosphorylates the tyrosine residues at the carboxy-terminal docking site (26). Phosphorylated MET (p-MET) networks with adaptor molecules such as Gab1 (GRB2-associated-binding protein 1), Grb2 (Growth factor receptor-bound protein 2), SRC (Sarcoma non-receptor tyrosine kinase), SHIP-1 (SH2 domain-containing inositol 5-phosphatase 1) and Shp2 (Src homology 2-domain-containing protein tyrosine phosphatase-2) to mediate biological responses (26,33-36). These effector molecules then activate downstream oncogenic signaling that regulates gene expression via the mitogen-activated protein kinase (ERK/MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K/AKT) pathways (Figure 1) (26,37,38). In addition to regulating gene expression, these effector molecules can alter cytoskeletal framework and cellular adhesion by modulating actin, catenin, integrins and cadherins via activation of the PAK1 (p21 Activated Kinase) (39).

Figure 1 Schematic representation of MET/HGF signaling and functional cross-talk with other pathways. Hepatocyte growth factor (HGF) binds to MET receptor and activates kinase activity which then phosphorylates the docking site and recruits effector molecules [Growth factor receptor-bound protein 2 (GRB2), GRB2-associated-binding protein 1 (GAB1), SRC homology 2 domain-containing phosphatase 2 (SHP2), Son of sevenless-1 (SOS-1) and Sarcoma non-receptor tyrosine kinase (SRC)]. Downstream signaling pathways such as the Mitogen-activated protein kinase (ERK/MAPK) pathway, the Phosphatidylinositol 3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ (PLC-γ) pathway are activated. These effector pathways are shared by the epidermal growth factor receptor (EGFR/EGF) pathway, the vascular epidermal growth factor (VEGFR-2/VEGF-A) pathway, the HER2 pathway and the EML4-ALK pathway. The signals affect gene expression and promote cell proliferation and survival, angiogenesis and cytoskeletal alterations resulting in cancer growth and progression. EGFR and HER2 can Trans-phosphorylate and activate MET. MET activation increases transcriptional expression of VEGF-A and WNT ligand and activates VEGF pathway and WNT-β-catenin pathway, respectively. β-catenin increases MET expression

Role in tumorigenesis

A normally functioning and strongly regulated MET/HGF axis is essential for embryogenesis, liver regeneration and wound healing (26,40-42). However, aberrant MET/HGF signaling promotes survival and migration of cells and can result in tumor development and progression. The cellular responses to activation of the MET/HGF axis support emergence of an oncogenic phenotype by promoting cellular proliferation, survival, migration, invasion and angiogenesis (43-46).

Aberrancy of the MET/HGF axis due to germline or somatic mutations has been implicated in various tumor types and linked with adverse clinicopathological profile and poor outcomes (26). The most frequent dysregulation in human cancers is due to over-expression of either the ligand HGF/SF or the receptor MET (47,48). Activating mutations of MET gene homologus to mutations seen in other RTKs are also seen but are uncommon (47,49). The MET/HGF pathway has been shown to be involved in carcinogenesis and progression of a variety of tumors such as head & neck squamous cell cancer, breast cancer and colon cancer (48,50-53). Aberrant MET/HGF expression in these tumors has also been shown to correlate with adverse clinicopathological factors such as higher grade, advanced stage and poor survival outcomes (50,54,55). The key role of MET/HGF in carcinogenesis has stimulated interest and investigation of the therapeutic potential of exploiting this axis for treatment of cancer (56,57).

Impact in lung cancer

MET, phosphorylated MET and HGF are highly expressed in both NSCLC and SCLC and appear to correlate with a worse overall survival (58). Although, HGF and MET are expressed in normal lung, their expression is increased in tumor tissue (59). In NSCLC cell lines and tumor tissues MET protein expression correlates with higher pathological tumor stage and worse outcomes (60). HGF induced MET phosphorylation in MET mutant SCLC cell lines promotes proliferation, invasiveness and clonogenic growth and its inhibition counteracts these effects (61). In human clinical samples, MET and p-MET overexpression is seen in 54% and 43% of SCLCs and is a poor prognostic factor (61).

This data has generated immense interest in therapeutic development of HGF/MET inhibition for lung cancer (56). Multiple clinical studies involving inhibition of MET/HGF axis are underway (62).

The MET/HGF axis: signaling pathways & cross-talk

Normal cellular physiology is regulated by a composite array of well-ordered signaling pathways. These complex axes are comprised of ligands, cell surface membrane receptors and intracellular signal transduction molecules. Anomalies in several of such cellular signaling pathways have been implicated in lung carcinogenesis. These aberrations regulate abnormal cellular proliferation, survival, motility and angiogenesis and consequently stimulate tumor growth and progression. Epidermal growth factor receptor (EGFR) pathway, vascular endothelial growth factor receptor (VEGFR) pathway and MET/HGF pathway are pathways of primary interest involved in lung cancer. A substantial functional cross-talk between the MET/HGF axis and these other signaling pathways has been demonstrated both in vitro and in vivo (63) (Figure 1). These functional relationships and resultant cellular functions in cancer cells are principal mechanisms for cancer progression and therapeutic resistance to targeted therapies.

MET/HGF & EGFR

EGFR is a valid target in NSCLC and plays a crucial role in the biological behavior of these tumors (64). EGFR mutations are seen in 15% to 30% of NSCLCs and are associated with better survival and responsiveness to EGFR inhibition with erlotinib and gefitinib (65,66). There appears to be a reciprocal functional cross-talk between the MET and the EGFR pathways (Figure 1). Activation of EGFR by EGFR ligands can lead to HGF-independent phosphorylation and activation of MET (67). This trans-phosphorylation indicates close cooperation among the EGFR and MET axis and can in part be responsible for cellular responses to EGFR stimulation. Furthermore, activation of the MET/HGF axis can cause EGFR independent stimulation of EGFR related downstream signaling pathways such as mitogen-activated protein kinase (ERK/MAPK) pathway and the phosphatidylinositol 3 kinase (PI3K-AKT) pathway (26).

MET/HGF & VEGFR

VEGF is a potent angiogenic factor that regulates angiogenesis and has prognostic significance in NSCLC (68). Evidence supports the role of MET/HGF axis as being involved in regulation of angiogenesis and lymphangiogenesis by promoting endothelial cell growth, migration and capillary formation (44,69). The MET/HGF axis also induces expression of VEGF-A by activation of MEK and PI3K pathway (70). HGF signals induce transcriptional activation of VEGF by enhancing promoter activity (71). In addition to the direct effect on endothelial cells and induction of VEGF-A, the axis also suppresses Thrombospondin-1, which is a negative regulator of angiogenesis (72). Akin to the EGFR pathway, the VEGF pathway and the MET/HGF axis also share a common assortment of downstream signaling pathways such as the MAPK pathway and the PI3K-AKT pathway (Figure 1).

MET/HGF & other pathways

HER2 overexpression is seen in 30% of patients with NSCLC and portends poor prognosis (73). Both HER2 and MET downstream signaling involves the MAPK and the PI3K pathways and recent data in breast cancer suggests that MET/HGF expression is associated with an increased risk of failure from trastuzumab based therapy in HER2-positive metastatic breast cancer (74).

The Wnt-β-Catenin pathway has been shown to be associated with c-myc and survivin gene expressions and tumor proliferation leading to progression and development of more aggressive tumors in NSCLC (75). There is significant crosstalk between MET/HGF axis and β-catenin signaling. The MET/HGF stimulation increases transcription of WNT ligands which in-turn inhibits β-catenin degradation complex thereby promoting β-catenin nuclear targeting and gene expression (62). Moreover, MET/HGF activation can result in WNT-independent PI3K mediated activation of β-catenin signaling (76,77). Conversely, an active form of β-catenin increases transcription of MET expression (77).

The ALK gene encodes for a receptor tyrosine kinase and the EML4-ALK fusion protein is a driver mutation in 5% to 13% of NSCLCs (14,78). The ALK tyrosine kinase activates downstream signaling pathways such as MAPK and PI3K pathway analogous to MET/HGF and promotes proliferation, migration and inhibits apoptosis (79). These shared signaling pathways and extensive cross-talk are an important consideration while evaluating the possible mechanisms of resistance to targeted therapies. Crizotinib, is a combined ALK and MET inhibitor, and its efficacy in NSCLCs is indicative of feasibility and effectiveness of co-inhibition of cooperating pathways (14,80).

The MET/HGF axis: resistance mechanism to contemporary therapies

Although, our armamentarium of treatment strategies has grown immensely, success has been limited. One of the foremost reasons for failure of contemporary treatments in lung cancer is presence of inherent or development of acquired resistance in cancer cells. Multiple mechanisms of resistance have been identified in lung cancer and MET/HGF axis is one of the pivotal cellular pathways contributing to this therapeutic resistance (Figure 2).

Figure 2 Schematic representation of mechanisms of resistance due to MET/HGF pathway and potential interventional strategies. Chemotherapy and radiotherapy damage DNA which in-turn increases nuclear factor kappa B (NF-κB) mediated increased expression of HGF and MET. MET [I] and/or HGF [II] over-expression are major mechanisms of resistance due to MET/HGF axis against contemporary therapies. VEGF inhibition can cause hypoxia and increased hypoxia-inducible factor-alpha (HIF-α) mediated HGF and MET expression. Rarely, mutations in the kinase domain [III] can cause constitutional activation of MET signaling and contribute to increased resistance. In gefitinib, erlotinib, cetuximab and bevacizumab resistant tumors, MET/HGF activates oncogenic signaling via Mitogen-activated protein kinase (ERK/MAPK) pathway, the Phosphatidylinositol 3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ (PLC-γ) pathway. The MET/HGF inhibition by HGF antagonists [A], anti-MET antibody [B] or small molecule receptor tyrosine kinase inhibitor (SmRTKI) [C] can help overcome resistance

Chemotherapy

Platinum based therapy is the backbone of conventional cytotoxic chemotherapy for NSCLC in both adjuvant setting and metastatic setting (7,11). It is also used in chemoradiation as a radiosensitizer (8). Furthermore, platinum agents are employed as first line therapy for both limited-stage and extensive-stage SCLC (18,19). Taxanes are extensively used in treatment of NSCLC (16). Camptothecins such as irinotecan and topotecan show activity in both NSCLC and SCLC and are used either as single agents or in combination with cisplatin/carboplatin (20,21,81,82). Anthracycline drugs such as epirubicin and etoposide are used in treatment of ES-SCLC (21,22). Development of chemotherapy-resistant phenotype is a principal cause of treatment failure in lung cancer.

MET/HGF axis has been frequently implicated in development of chemoresistance in multiple tumor types (Figure 2). Cytotoxicity in human glioblastoma tumor cell lines from gamma irradiation, cisplatin, camptothecin, Adriamycin and taxanes has been shown to be partially abolished by pretreatment with recombinant HGF in vitro (83). This cytoprotective effect from HGF is a result of inhibition of apoptosis, mediated by MET/HGF signaling that activates PI3K-AKT pathway (83). Studies have also demonstrated that HGF transfected Chinese hamster ovary cells are resistant to treatment with cytotoxic DNA damaging agents such as Adriamycin and irinotecan. The increased cell viability was the result of decreased apoptotic cell death induced by these agents indicating the protective effect of HGF against programmed cell death following DNA damage (84). Rhabdomyosarcoma cell lines overexpressing HGF and MET exhibit increased survival even on exposure to chemotherapy (85).

Multiple mechanisms of MET/HGF induced-chemoresistance have been proposed (Figure 2). Most cytotoxic agents promote apoptosis through programmed cell death (86). The MET/HGF axis down-regulates the expression of anti-apoptotic protein Bcl-XL (87). MET/HGF also inhibits N-methyl-d-aspartate (NMDA)-induced activation of caspase 3 and NMDA-induced apoptosis-inducing factor (AIF) translocation from mitochondria to nucleus thereby preventing NMDA-induced cell death in cultured hippocampal neurons (88). Similarly, HGF suppresses AIF expression through activation of FAK and induces cisplatin resistance in lung cancer cell lines (89). Additionally, DNA damaging agents such as Adriamycin, camtothecins, cisplatin and etoposide induce translocation of AIF, a mitochondrial effector of apoptotic cell death, from mitochondria to nucleus (90). A possible mechanism for this translocation is activation of poly (ADP-ribose) polymerase-1 (PARP-1), which protects the genome by functioning as a DNA damage surveillance network, by DNA damaging agents (91). PARP-1 activation induces translocation of AIF which induces caspase-independent chromatin condensation and DNA fragmentation (91-93). AIF-mediated apoptotic death is critical for treatment effect in NSCLC cell lines (94). MET/HGF mediated inhibition of AIF is therefore a potential mechanism for resistance to cytotoxic chemotherapy in lung cancer.

This data illustrates a vital role of the MET/HGF axis in conferring chemoresistance to common cytotoxic chemotherapy in lung cancer. MET/HGF inhibition can therefore be used strategically to overcome chemoresistance and improve response rates and survival outcomes with conventional chemotherapy.

Radiation

Radiotherapy forms the cornerstone of combined-modality therapy for unresectable stage III NSCLC and LS-SCLC (19,95). In NSCLC, complete response (CR) rate with concurrent chemoradiotherapy is about 40% and 5-year OS is about 16% (8). Similarly, SCLC, which is radiosensitive tumor, CR rate with concurrent chemoradiation is about 50% and median OS is about 2 years (96). Radiotherapy resistance is a probable mechanism for these sub-optimal response rates and recurrent disease despite aggressive treatment.

Radiation causes DNA damage and the resultant cellular radiosensitivity in cancers is a function of activation of apoptotic programmed cell death (97,98). Therefore, acquired cellular insensitivity to radiation therapy is in part caused by activation of anti-apoptotic signals such as the PI3K/AKT pathway (99). Notably, the PI3K/AKT pathway can also be activated by MET/HGF signaling (26,99). Additionally, radiation induced hypoxia can cause transcriptional activation of MET proto-oncogene (100). This effect is mediated by initial recognition of radiation-induced DNA damage by the ATM protein kinase, which in turn activates nuclear-factor kappa B (NF-κB) (101). The NF-κB binds to the MET promoter and increases MET expression (Figure 2) (101).

Multiple studies have corroborated stimulation of MET/HGF axis by radiation. In human malignant glioma cell lines, radiation exposure leads to a dose-dependent increase of HGF levels and development of radioresistance (102). In lung cancer and pancreatic cell lines, gamma-radiation leads to substantially increased MET expression and phosphorylation (101,103). HGF ligand in presence of such upregulated MET receptors abolishes radiation-compromised cell migration and can lead to emergence of metastatic phenotypes (103). The overexpressed MET receptor in such irradiated cell lines possesses constitutively activated kinase activity and phosphorylation as well as increased sensitivity to HGF ligand (101). These results were reproduced in a panel of neuroblastoma cell lines, which when exposed to radiation showed enhanced HGF mRNA expression and MET receptor amplification (104). Both ligand-dependent and ligand-independent phosphorylation of MET was seen in such cell lines (104). Similarly, HGF and MET overexpression has also been shown to increase survival in rhabdomyosarcoma cell lines exposed to radiotherapy (85). This data illustrates the importance of MET/HGF in development of acquired resistance to radiotherapy (101).

The presence of residual disease after radiation therapy and disease relapse after initial responses indicates emergence of radio-resistant cancer cells and MET/HGF appears to play a significant role in this phenomenon. Radiotherapy in combination with MET/HGF inhibition, used as a radiosensitizer, is hence a promising therapeutic partnership.

Targeted therapies

Systemic palliative management of metastatic NSCLC is individualized based on mutational profile of the tumors. The molecular characterization to date involves evaluating for mutations against which, efficacious targeted therapies are available and include EGFR mutations or expression (erlotinib, gefitinib, and cetuximab) and EML/ALK4 rearrangement (crizotinib) (14,15,17). Bevacizumab in combination with chemotherapy improves survival in adenocarcinomas (16). However, responses are still restricted and disease progression occurs invariably. Despite the sound scientific rationale of anti-angiogenesis, the 2 months improvement in overall survival with addition of bevacizumab to chemotherapy in the E4599 trial was not duplicated in the AVAiL trial (16,105). Similarly, increase in response rates to addition of cetuximab in EGFR expressing tumors was only about 20% and median OS improved by about 1.2 months (17). Although, gefitinib therapy in WJTOG3405 trial was associated with a response rate of 60%, the progression-free survival was only increased by 3 months (106). As is evident from above data, a majority of patients initially respond to targeted therapies but subsequently develop disease progression possibly as a result of emergence of acquired resistance and alterations in the MET/HGF signaling cascade appear to be a key player in this phenomenon (Figure 2).

EGFR inhibition resistance

The functional cross-talk between the EGFR and MET pathway is clinically significant and is probably responsible for both primary and acquired resistance against EGFR directed therapies in lung cancer. It has been established that dual receptor activation of cell lines co-expressing EGFR and MET, results in increased proliferation of such cell lines (107).

Although, EGFR expression is common in lung cancers, only a minority of patients respond to cetuximab due to presence of primary resistance and most of those who respond do so only transiently due to acquired resistance. Increased MET/HGF activity is a possible mechanism of this resistance. Cells previously treated with cetuximab, when cultured with HGF exhibit MET phosphorylation and revamped stimulation of downstream effector pathways (MAPK and PI3K/AKT) which restore cell proliferation and prevents apoptosis (108). Similarly, patient-derived xenografts from NSCLC demonstrated that MET overexpression from gene amplification and activation is a major mechanism of primary cetuximab resistance (108). The HGF induced resistance to cetuximab is seen regardless of EGFR gene status in both wild-type and mutant EGFR cells (109).

Small molecule EGFR tyrosine kinase inhibitor such as gefitinib, are effective in NSCLC and act via reduction of ErbB-3 mediated PI3K/AKT growth signaling (110). Both primary and secondary resistance mechanisms to EGFR-TKIs in NSCLC have been described (111). Although, secondary T790M mutation in EGFR is the most common cause (50%) of acquired resistance to EGFR-TKIs, multiple other pathways are also involved (112,113). MET/HGF has been identified as a novel mechanism of resistance to EGFR-TKIs (114). Only about 10% of unselected NSCLC patients respond to EGFR-TKIs and strong MET membrane immunoreactivity has been shown to be associated with progressive disease and shorter time to progression and thus may be regarded as marker of primary gefitinib resistance in NSCLC patients (115). MET/HGF signaling activates PI3K/AKT pathway and may contribute to gefitinib resistance using this downstream effector pathway (26). Study with a gefitinib-sensitive lung cancer cell line demonstrated that acquired resistance to gefitinib develops as a result of focal amplification of the MET proto-oncogene (116). MET amplification is seen in 22% of lung cancer specimens that develop resistance to gefitinib or erlotinib possibly due to re-activation of PI3K pathway (116). Similarly, HGF-mediated MET activation has also been shown to confer gefitinib resistance in lung adenocarcinomas (117).

VEGFR inhibition resistance

Bevacizumab in combination with chemotherapy is used in NSCLC and improves response rates but these responses are not universal and often short lived (16). The MET/HGF axis promotes angiogenesis by promoting endothelial cell growth, migration and capillary formation, induces expression of VEGF-A and suppresses Thrombospondin-1 thereby contributing to resistance against VEGF inhibition (44,70,72). Hypoxia promotes transcriptional activation of MET (100). Dual inhibition of MET and VEGFR-2 has demonstrated strong inhibition of tumor growth and tumor angiogenesis in xenograft models (118).

Others

Multiple molecular pathways have been shown to be involved in carcinogenesis of lung neoplasms. The limited single-agent clinical activity demonstrated by several targeted agents in lung cancer begs the question that, are there intrinsic resistance pathways that overcome single pathway inhibitions? Understanding these resistance mechanisms is essential to hypothesize rational combinations that would enhance cytotoxic effects and exploit the full potential of targeted therapies.

HER2 expression is seen in 30% of NSCLCs and 25% of SCLCs and is associated with poor prognosis (73,119). HER2 overexpression in NSCLC is also a marker for multidrug resistance (120). Anti-Her2 therapy has shown significant anti-tumor effect against NSCLC, both in vivo and in vitro (121,122). However, multiple trials of trastuzumab in NSCLC have failed to show any significant clinical activity (123,124). MET expression has been shown to contribute to trastuzumab resistance in breast cancer and could be a factor contributing to suboptimal responses to trastuzumab in NSCLC (124,125). Anti-Her2 therapy could be therapeutic strategy in NSCLC due to significant expression seen in NSCLC and also since HER2 expression can contribute to angiogenesis by enhancing VEGF secretion (126).

Histone deacetylase 1 (HDAC1) expression in lung cancer is associated with poor 5-year disease-free survival rate (127). Histone deacetylase inhibitors such as vorinostat can induce tumor cell growth arrest, differentiation and apoptosis. A phase II trial of vorinostat carboplatin plus paclitaxel showed increased response rate with vorinostat (128). HDAC regulates chromatin remodeling and down-regulates transcription of miR-449, which is an inhibitor of MET expression (129). MET/HGF overexpression can therefore potentially lead to resistance against HDAC inhibitors.

Future

General

Treating lung cancer has been a daunting task. A myriad of therapies are available but outcomes remain below par. Molecular characterization of lung cancer has taught us that this disease is heterogeneous and that molecular pathology guides prognosis and response to therapy. The MET/HGF pathway has been identified as a novel driver of lung carcinogenesis. Besides its role as a mitogen, motogen and angiogen, MET/HGF also plays a key role in both primary and acquired resistance to contemporary therapies. The potential role of the MET/HGF axis as a predictive and prognostic marker needs further exploration.

Potential for therapeutic interventions

MET/HGF axis has recently emerged as a potential therapeutic target and multiple agents including monoclonal antibodies to either the MET receptor or HGF and small molecular tyrosine kinase inhibitors against MET RTK are being investigated (130). Recognition of the role of MET/HGF axis as a potent resistance mechanism has steered interest in development of therapeutic strategies using MET/HGF inhibition to overcome resistance to contemporary therapies in lung cancer (131).

Inhibition of the MET receptor by gene transfer in tumor cell lines inhibits the cytoprotective anti-apoptotic effect of HGF against DNA-damaging agents such as gamma irradiation, cisplatin, camptothecin, Adriamycin and taxanes (83). Combination of MET/HGF inhibitors with chemotherapy can possibly improve tumoricidal activity of cytotoxic chemotherapy and improve response rates and outcomes.

Viability of irradiated radio-resistant tumor cell lines treated with MET inhibitor is reduced dramatically after irradiation as a result of increased caspase-3 mediated apoptosis (101). Moreover, treatment with MET inhibitor decreased proliferative capacity of cells that survived irradiation (101). Xenografts using these cell lines showed a significant decrease in tumors when treated with radiation and MET inhibition as compared to radiation alone (101). Recombinant HGF antagonist can block enhanced malignant potential of tumors by radiation-induced MET/HGF amplification thereby improving the efficacy of radiotherapy (103). Similarly, targeting endogenous expression of HGF and MET in human malignant glioma cells and xenografts sensitizes cells to gamma-radiation and enhances radiation-induced caspase-dependent cytotoxicity (132). These studies provide proof of concept regarding synergistic antitumor response of radiation and MET/HGF inhibition (132).

MET inhibition by selective tyrosine kinase inhibitors or downregulation of MET expression by a specific siRNA has been shown to abolish the HGF induced cetuximab resistance in cell lines and restore growth-inhibitory effects of cetuximab (107). MET knockdown not only restores cetuximab resistance but also reduces EGF stimulated EGFR phosphorylation (108). Cetuximab resistance due to HGF can also be abrogated by treatment with anti-HGF neutralizing antibody (109). HGF mediated resistance to gefitinib in lung cancer cell lines can be reversed by down-regulation of MET expression by MET-specific siRNA (117). HGF induced hyposensitivity to EGFR-TKI can be abrogated by treatment with anti-HGF neutralizing antibody, HGF antagonist or MET-TKI (114). A phase II trial of ARQ197 plus erlotinib, a small molecule inhibitor of MET receptor, in NSCLC showed evidence of activity with this combination (133). As a result of this trial, MARQUEE, a phase III, randomized, placebo-controlled study has been initiated in NSCLC patients with the rationale that dual inhibition of MET and EGFR may overcome resistance to EGFR inhibitors (134). Therapy with MET/HGF inhibitors and EGFR inhibitors hold promise for select patients who either fail to respond to anti-EGFR therapy or acquire resistance after an initial response.

Combined MET and VEGF inhibition has been shown to be effective in inducing tumor regression and also in overcoming HGF-induced EGFR-TKI resistance (118,135). Valproic acid, a HDAC inhibitor, has been shown to inhibit HGF expression and HGF mediated invasion in hepatocellular carcinoma cells (136). Additionally, SCLC cell lines exposed to HDAC inhibitors and topoisomerase inhibitors showed an additive-synergistic response and decreased cell viability (137). Triple target inhibition using combination of MET, EGFR and Her2 inhibitors has illustrated that even though each drug alone was not very effective, the combination resulted in a synergistic inhibition of proliferation and more cytotoxicity (138). MET inhibition has been shown to restore sensitivity to anti-Her2 in cell lines (138). The existing data provides a conceptual framework for combining various targeted therapies with MET/HGF inhibitors to improve tumor kill.

MET/HGF has the potential to emerge in future as a chief molecular target that can be manipulated pharmacologically to increase tumor-cell cytotoxicity. Combined treatments of MET/HGF inhibitors and other contemporary therapies in selected lung cancer patients could result in pronounced clinical benefits.

Acknowledgements

Drs. Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo and George R. Blumenschein, Jr. have contributed significantly in writing and editing the manuscript. All authors are in agreement with the contents of the manuscript. No federal or industry support was involved in the preparation of this manuscript.

This work was supported in part The Susan G. Komen Foundation SAC100004 (to AMG, GRB).

Disclosure: Ana Maria Gonzalez-Angulo and George R. Blumenschein, Jr. have research funding from Genentech, EMD Serono, and Exelixis.

References

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007;11:89-96.
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
5. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
6. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
7. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
8. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60.
9. Falk SJ, Girling DJ, White RJ, et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 2002;325:465.
10. Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968;90:688-97.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
13. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991;14:115-9.
14. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
15. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
17. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
18. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002;20:4665-72.
19. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-7.
20. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
21. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044-51.
22. Artal-Cortés A, Gomez-Codina J, Gonzalez-Larriba JL, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 2004;6:175-83.
23. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer [Adjuvant Navelbine International Trialist Association (ANITA)]: a randomised controlled trial. Lancet Oncol 2006;7:719-27.
24. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
25. Dean M, Park M, Le Beau MM, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985;318:385-8.
26. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
27. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
28. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
29. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
30. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
31. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 2003;100:12039-44.
32. Chirgadze DY, Hepple JP, Zhou H, et al. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 1999;6:72-9.
33. Schaeper U, Gehring NH, Fuchs KP, et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 2000;149:1419-32.
34. Sachs M, Brohmann H, Zechner D, et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol 2000;150:1375-84.
35. Weidner KM, Di Cesare S, Sachs M, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996;384:173-6.
36. Stefan M, Koch A, Mancini A, et al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. J Biol Chem 2001;276:3017-23.
37. Cunnick JM, Meng S, Ren Y, et al. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem 2002;277:9498-504.
38. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98:247-52.
39. Royal I, Lamarche-Vane N, Lamorte L, et al. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell 2000;11:1709-25.
40. Borowiak M, Garratt AN, Wustefeld T, et al. Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 2004;101:10608-13.
41. Chmielowiec J, Borowiak M, Morkel M, et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007;177:151-62.
42. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702-5.
43. Brinkmann V, Foroutan H, Sachs M, et al. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573-86.
44. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
45. Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42.
46. Weidner KM, Behrens J, Vandekerckhove J, et al. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990;111:2097-108.
47. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-37.
48. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998;108:1413-7.
49. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
50. Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012;18:2269-77.
51. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54.
52. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55.
53. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 1997;27:378-83.
54. Lo Muzio L, Farina A, Rubini C, et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol 2006;27:115-21.
55. De Oliveira AT, Matos D, Logullo AF, et al. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009;29:4807-11.
56. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010;46:1260-70.
57. Liu X, Yao W, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011.
58. Tretiakova M, Salama AK, Karrison T, et al. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol 2011;30:341-54.
59. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74:1862-8.
60. Ichimura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87:1063-9.
61. Arriola E, Canadas I, Arumi-Uria M, et al. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer 2011;105:814-23.
62. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
63. Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 2006;5:1676-82.
64. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001;7:1850-5.
65. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
66. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
67. Yamamoto N, Mammadova G, Song RX, et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006;119:4623-33.
68. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-32.
69. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.
70. Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-8.
71. Reisinger K, Kaufmann R, Gille J. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci 2003;116:225-38.
72. Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-23.
73. Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27:1372-5.
74. Minuti G, Cappuzzo F, Duchnowska R, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 2012;107:793-9.
75. Nakashima N, Liu D, Huang CL, et al. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer 2012;76:228-34.
76. Rasola A, Fassetta M, De Bacco F, et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene 2007;26:1078-87.
77. Boon EM, van der Neut R, van de Wetering M, et al. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002;62:5126-8.
78. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
79. Pearson JD, Lee JK, Bacani JT, et al. NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. J Signal Transduct 2012;2012:123253.
80. Atkinson YH, Murray AW, Krilis S, et al. Human tumour necrosis factor-alpha (TNF-alpha) directly stimulates arachidonic acid release in human neutrophils. Immunology 1990;70:82-7.
81. Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994;34:S105-11.
82. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:2800-7.
83. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000;60:4277-83.
84. Meng Q, Mason JM, Porti D, et al. Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration. Biochem Biophys Res Commun 2000;274:772-9.
85. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926-35.
86. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541-6.
87. Fan S, Wang JA, Yuan RQ, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998;17:131-41.
88. Ishihara N, Takagi N, Niimura M, et al. Inhibition of apoptosis-inducing factor translocation is involved in protective effects of hepatocyte growth factor against excitotoxic cell death in cultured hippocampal neurons. J Neurochem 2005;95:1277-86.
89. Chen JT, Huang CY, Chiang YY, et al. HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol 2008;38:559-65.
90. Daugas E, Nochy D, Ravagnan L, et al. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 2000;476:118-23.
91. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002;297:259-63.
92. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
93. Candé C, Cohen I, Daugas E, et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002;84:215-22.
94. Gallego MA, Joseph B, Hemstrom TH, et al. Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 2004;23:6282-91.
95. O’Rourke N, Roque IFM, Farre Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010:CD002140.
96. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
97. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004;4:737-47.
98. Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009;9:351-60.
99. Zhan M, Han ZC. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 2004;19:915-23.
100. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
101. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-61.
102. Sheng-Hua C, Yan-Bin M, Zhi-An Z, et al. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg Neurol 2007;68:610-3; discussion 3-4.
103. Qian LW, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer 2003;104:542-9.
104. Schweigerer L, Rave-Frank M, Schmidberger H, et al. Sublethal irradiation promotes invasiveness of neuroblastoma cells. Biochem Biophys Res Commun 2005;330:982-8.
105. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
106. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
107. Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.
108. Krumbach R, Schüler J, Hofmann M, et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011;47:1231-43.
109. Yamada T, Takeuchi S, Kita K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012;7:272-80.
110. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
111. Ayoola A, Barochia A, Belani K, et al. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012;30:433-46.
112. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
113. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9.
114. Yamada T, Matsumoto K, Wang W, et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010;16:174-83.
115. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-12.
116. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
117. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87.
118. Nakagawa T, Tohyama O, Yamaguchi A, et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010;101:210-5.
119. Micke P, Hengstler JG, Ros R, et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-9.
120. Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-901.
121. Kern JA, Torney L, Weiner D, et al. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol 1993;9:448-54.
122. Skrepnik N, Araya JC, Qian Z, et al. Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin Cancer Res 1996;2:1851-7.
123. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.
124. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004;22:1180-7.
125. Shattuck DL, Miller JK, Carraway KL 3rd, et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008;68:1471-7.
126. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-9.
127. Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011;74:300-4.
128. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62.
129. Buurman R, Gürlevik E, Schäffer V, et al. Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. Gastroenterology 2012;143:811-20.
130. Belalcazar A, Azana D, Perez CA, et al. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther 2012;12:519-28.
131. Bonanno L, Jirillo A, Favaretto A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr Drug Targets 2011;12:922-33.
132. Lal B, Xia S, Abounader R, et al. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 2005;11:4479-86.
133. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15.
134. Scagliotti GV, Novello S, Schiller JH, et al. Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2012;13:391-5.
135. Takeuchi S, Wang W, Li Q, et al. Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. Am J Pathol 2012;181:1034-43.
136. Matsumoto Y, Motoki T, Kubota S, et al. Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. Biochem Biophys Res Commun 2008;366:110-6.
137. Gray J, Cubitt CL, Zhang S, et al. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 2012;13:614-22.
138. Agarwal S, Zerillo C, Kolmakova J, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009;100:941-9.